|Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patents - Monitor Patents|
USPTO Class 530 | Browse by Industry: Previous - Next | All
Recent | 14: | | | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn | | 2008 | 2007 |
Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereofBelow are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application. 12/04/2014 > 11 patent applications in 11 patent subcategories.
20140357837 - Novel protein peptide hydrogels: The present invention broadly provides novel peptides that can be used to form hydrogels. The peptides are short (preferably 30 amino acid residues or less) and include hydrophilic and hydrophobic segments joined by a turning segment. The hydrogels are formed by altering the pH of a solution of these peptides... Agent:
20140357838 - N-terminally modified insulin derivatives: The invention is related to novel N-terminally modified insulin derivatives comprising extra disulphide bond(s), pharmaceutical compositions comprising such and methods of making such.... Agent: Novo Nordisk A/s
20140357839 - Vancomycin b hydrochloride crystalline form 1: Vancomycin B Hydrochloride Crystalline Form 1, compositions containing it and methods of prevention or treatment of bacterial infections using it are disclosed.... Agent:
20140357840 - Method for obtaining a dialyzable leukocyte extract: The present invention relates to a method for producing a transfer factor. The method comprises the following steps: freezing and thawing of peripheral-blood leukocytes, dialysis, tangential ultrafiltration, identification and quantification using high-resolution, molecular-exclusion liquid chromatography, and in vitro biological validation. The resulting product is suitable for medical use.... Agent:
20140357841 - Method for stabilizing polypeptide into alpha helix: A method for stabilizing an alpha helix of a polypeptide includes steps of: (1) connecting an unnatural amino acid to an amino terminus of the polypeptide and end-capping via an acetylation; (2) processing a product of the step (1) with a thiolene reaction and obtaining a polypeptide compound having a... Agent: Peking University Shenzhen Graduate School
20140357842 - Yersinia outer protein m (yopm) in the treatment of psoriasis: The present invention relates to the use of Yersinia outer protein M (YopM)in the prevention and/or treatment of psoriasis by cutaneous, intradermalor subcutaneous administration. In particular, the present invention relates to the use of YopM in the treatment of plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, arthritis... Agent: Westfaelische Wilhelms-universitaet Muenster
20140357843 - Immunoglobulin fc variants: The present invention relates to immunoglobulin Fc variants having an increased binding affinity for FcRn, which is characterized by including one or more amino acid modifications selected from the group consisting of 307S, 308F, 380S, 380A, 428L, 429K, 430S, 433K and 434S (this numbering is according to the EU index)... Agent: Hanmi Science Co., Ltd
20140357844 - Antibodies specific for trop-2 and their uses: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the... Agent:
20140357845 - Influenza virus vaccines and uses thereof: The present disclosure provides influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment, covalently linked by a linking sequence of 0-50 amino acid residues to an HA1 C-terminal stem segment, and (b) an influenza hemagglutinin HA2 domain, wherein on or... Agent:
20140357846 - Thyroid stimulating hormone compositions: Described herein are compositions of Thyroid Stimulating Hormone (TSH), wherein at least one polyalkylene glycol polymer is attached to a carbohydrate site of the TSH. Also described are compositions of mutated Thyroid Stimulating Hormone (TSH) and at least one polyalkylene glycol polymer, wherein the mutated TSH comprises a TSH in... Agent:
20140357847 - Method for lignin separation from black liquor having removal of sulphur compounds from formed water effluent: The method is for separation of lignin from original black liquor (BLIN) having a first precipitation phase (PR1/PR2) for precipitation of lignin by a first acidification using acidifier, CO2, at alkaline conditions, then separating a lignin cake with subsequent suspension of the lignin cake in a strong acid to leach... Agent:11/27/2014 > 13 patent applications in 8 patent subcategories.
20140350218 - Alpha-conotoxin peptides: The invention relates to relatively short peptides (termed α-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.... Agent: The University Of Utah Research Foundation
20140350217 - Functional lipid constructs: The invention relates to methods for effecting qualitative and quantitative changes in the functional moieties expressed at the surface of cells and multi-cellular structures, and functional lipid constructs for use in such methods. In particular, the invention relates to functional lipid constructs and their use in diagnostic and therapeutic applications,... Agent: Kode Biotech Limited
20140350219 - Method for solid phase synthesis of liraglutide: Provided is a method for solid phase synthesis of liraglutide, comprising the following steps: A), Fmoc-Gly-resin being obtained by coupling resin solid phase carrier with glycine with N-end protected by Fmoc(Fmoc-Gly-OH) in the presence of activator system; B) according to the peptide sequence of the main chain of liraglutide, successively... Agent: Hybio Pharmaceutical Co., Ltd.
20140350221 - Method for determining intrinsic binding parameters of an analyte to a ligand, a method for selecting an analyte from a group of analytes, the selected ligand or analyte, and sensor: The present invention relates to a method for determining intrinsic binding parameters, such as KD, kd and ka, of an analyte to a ligand, such as a drug and a protein, a drug and a receptor, and an antibody and antigen, wherein the maximal binding response Rmax or RL and... Agent:
20140350222 - Microalgal extraction: Disclosed herein is a process for extracting lipid containing products from microalgal biomass, the process comprising: (i) treating an aqueous mixture comprising microalgal biomass with microwave radiation and (ii) recovering lipid containing products from the treated microalgal biomass.... Agent:
20140350220 - Novel surface exposed haemophilus influenzae protein (protein; pe): The present invention relates to a surface exposed protein (protein E; pE), a virulence factor, which can be detected in Haemophilus influenzae, having an amino acid sequence as described in SEQ ID NO: 1, an immunogenic fragment of said surface exposed protein, and a recombinant immunogenic protein (pE (A)) or... Agent:
20140350223 - Enhanced production and purification of a natural high intensity sweetener: Recombinant P. pastoris producing natural sweet proteins and methods for engineering these recombinant yeast are described. Methods for enhancing foreign protein production in yeast fermentation and improved methods for purification of foreign proteins produced in yeast fermentation are presented.... Agent: Tate & Lyle Technology Limited
20140350224 - Foamed personal care composition obtainable by aerating and heating a base composition: Foamed personal care composition obtainable by aerating a base composition and heating at from 30 to 100° C. for from 10 minutes to 100 hours. The composition comprises a proteinaceous material and is suitable for use in care of the hair.... Agent: Conopco, Inc., D/b/a Unilever
20140350225 - Anti-bfgf humanized double-stranded antibody with stable disulfide bond, preparation method and application thereof: Disclosed are an anti-bFGF humanized double-stranded antibody with stable disulfide bond, the preparation method and the applications thereof. The amino acid sequence of the anti-bFGF humanized ds-Diabody is shown in SEQ ID NO. 1. The nucleotide sequence of gene encoding the anti-bFGF humanized ds-Diabody is shown in SEQ ID NO.... Agent: Jinan University
20140350226 - Rspondins as modulators of angiogenesis and vasculogenesis: The present invention relates to the use of Rspondins, particularly Rspondin2 (Rspo2) or Rspondin3 (Rspo3) or Rspondin nucleic acids, or regulators or effectors or modulators of Rspondin, e.g. Rspo2 and/or Rspo3 to promote or inhibit angiogenesis and/or vasculogenesis, respectively. The invention is based on the demonstration that Rspo3 and Rspo2... Agent:
20140350228 - Use of n-hydroxysuccinimide to improve conjugate stability: The invention provides processes for manufacturing cell-binding agent-cytotoxic agent conjugates of improved stability in the presence of exogenous NHS. In some embodiments, the inventive process comprises the addition of a molar ratio of exogenous NHS with respect to the amount of NHS generated during the modification reaction as a result... Agent: Immunogen, Inc.
20140350229 - Method for producing synthetic amylospheroid: Provided is a method for producing synthetic amylospheroids efficiently, the method including agitating a liquid containing amyloid β-peptides in the presence of a plasticizer. Amylospheroid refers to an assembly of amyloid β-peptides that selectively can induce cell death of functionally mature neurons. Amylospheroid is considered to play a central role... Agent:11/20/2014 > 12 patent applications in 10 patent subcategories.
20140343248 - Method for enhancing immune response with peptide: An object of the present invention is to provide a safe and effective method for enhancing an immune response and a medicament for preventing or treating Alzheimer disease comprising amyloid β peptide that induces an enhanced immune response. An amyloid β peptide or a portion thereof with addition or insertion... Agent: The Chemo-sero-therapeutic Research Institute
20140343249 - Cell killing fusion peptide exhibiting tumor cell-specific necrosis induction and tumor regression: A cell-killing peptide, more specifically a cell-killing CKP fusion peptide (CTD7:CKP) is disclosed, wherein a cell-killing peptide (CKP) comprising 10 amino acids in MTD of Noxa protein causing cell death, and 7 amino acids targeting a cancer cell are fused. The cell-killing CKP fusion peptide induces strong cell necrosis at... Agent: Industry-academic Cooperation Foundation, Chosun University
20140343251 - Agents and methods for the expression and secretion of peptides and proteins: The present invention relates to a nucleic acid molecule for recombinant expression and secretion of a peptide or protein of interest comprising a hemolysin A and/or hemolysin C-derived nucleotide sequence, fragments thereof, homologs thereof, or the complements thereof, and a nucleotide sequence encoding the peptide or protein of interest.... Agent: Heinrich-heine-universitaet Duesseldorf
20140343250 - Recombinant bacteria recognizing protein and uses thereof: The present invention relates to a recombinant protein comprising SEQ ID NO: 1 and a bacteria recognizing lectin. The present invention also relates to uses of the recombinant protein comprising detecting pathogens, removing endotoxins, determining the presence of an endotoxin or endotoxin-like material, and determining the presence of pathogen-associated molecular... Agent: Simpson Biotech Co., Ltd.
20140343252 - Interleukin-2 muteins for the expansion of t-regulatory cells: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also,... Agent: Amgen Inc.
20140343253 - Plasma protein fractionation by sequential polyacid precipitation: There is a recognized need for novel, more simplified, approaches to isolation of plasma from whole blood, as well as a need to isolate cell-free plasma fractions containing different plasma proteins. Methods are divulged for use of aqueous phase systems, formed in blood or blood containing solutions via addition of... Agent: Ge Healthcare Bio-sciences Ab
20140343254 - Tobacco-derived protein compositions: The disclosure describes methods for the purification of protein-enriched extracts to provide concentrates and isolates and methods for incorporation of such materials into products. The purification methods are adapted for removal of one or more of ash, metal salts, alkaloids, particulates, heavy metals, and other impurities and/or contaminants from extracts,... Agent:
20140343255 - Two-stage ultrafiltration/diafiltration: The present invention provides a method for concentrating a protein, in particular a method for concentrating a plasma product, in particular IgG, using glycine in a two-stage ultrafiltration/diafiltration approach.... Agent: Grifols Therapeutics Inc.
20140343257 - Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders: The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides, to methods for preparing such amino acid sequences and polypeptides, to host cells expressing or capable of expressing such amino acid sequences or polypeptides, to compositions, and in particular to pharmaceutical compositions, that comprise such amino... Agent: Ablynx N.v.
20140343256 - Tlr2 antagonistic antibody and use thereof: The present invention is directed to a cross-reactive antibody, which specifically inhibits or blocks the mammalian Toll-like receptor 2 (TLR2)-mediated immune cell activation. The invention is further directed to an isolated nucleic acid or vector coding for the variable regions of the heavy and/or light chain of said antibody. It... Agent: Technische Universitaet Munchen
20140343258 - Novel anti-human ctgf antibody: e
20140343259 - Protein product: A protein product recovered from a fermentation process including a protein content of 45.0% or more calculated by weight of dry matter, a glycerol content of 1.0% or less calculated by weight of dry matter, and a mineral nutrient content of 6.0% or less calculated by weight of dry matter.... Agent: Valicor, Inc.11/13/2014 > 13 patent applications in 9 patent subcategories.
20140336355 - Ion-exchanger material with high salt-tolerance: The present invention relates to a crosslinked sulphonated polymer or a crosslinked sulphonated polymer coated with a crosslinked polymer containing amino groups for use as an ion exchanger material of high salt tolerance for separating off macromolecules from a solution which originates from a biological source.... Agent: Instraction Gmbh
20140336356 - Peptide agonists of glp-1 activity: Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose... Agent: Zealand Pharma A/s
20140336357 - Microbial nanowires: The application describes electrically conductive nanowires, as well as genetically and/or chemically modified nanowires with modified conductive, adhesive and/or coupling properties.... Agent:
20140336358 - Methods and compositions for tumor vaccination and therapy: The present invention relates to peptide vaccines, pharmaceutical compositions thereof, and associated methodologies that promote the immune-mediated regression of tumors expressing an onconeural antigen, e.g. a cdr-2 antigen, HuD antigen. The cancer peptide vaccines of the present invention are antigenic peptides capable of being faithfully presented on the MHC I... Agent: Rockefeller University (the)
20140336359 - Synthetic peptides for treatment of bacterial infections: Disclosed are peptides and methods for the treatment of bacterial infections and associated inflammation. Effective doses and treatment protocols are disclosed.... Agent:
20140336363 - Antibodies against human csf-1r and uses thereof: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.... Agent: Hoffmann-la Roche Inc.
20140336361 - Assembly of bispecific antibodies: Described herein are methods for the efficient production of a heteromultimeric protein, such as a bispecific antibody. Heteromultimeric proteins may be capable of specifically binding to more than one target molecule or different epitopes on a single target molecule. The methods modulate parameters to improve assembly of the heteromultimeric proteins... Agent: Genentech, Inc.
20140336362 - Avian derived antibodies: The invention is drawn to a composition comprising an isolated mixture of cytotoxic anti-CD20 antibody molecules produces in a transgenic avian. The antibody molecules have a heavy chain and a light chain and exhibit an increased level of antibody-dependent cell-mediated cytotoxicity (ADCC) as compared to that of anti-CD20 antibody molecules... Agent: Synageva Biopharma Corp.
20140336360 - Tyrosine, serine and threonine phosphorylation sites: The invention discloses 155 novel phosphorylation sites identified in carcinoma and leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.... Agent:
20140336364 - Monoclonal antibody against interferon-gamma (ifn-gamma) inducing factor (ifig, il-18): A protein which induces the IFN-γ production by immunocompetent cells and has a molecular weight of 19,000±5,000 daltons on SDS-PAGE or gel filtration method and a pI of 4.8±1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The... Agent:
20140336365 - Cdr regions of monoclonal antibody that antagonize sphinogosine 1-phosphate and related methods: Materials and method for treating cancer and screening for anti-neoplastic agents are provided. These materials and methods can include sphingosine 1-phosphate antagonists that bind to sphingosine-1 phosphate receptor subtype 3. Antibodies and aptamers that selectively bind to an epitope in the extracellular loop between transmembrane domains two and three of... Agent:
20140336366 - Bioconjugate vaccines made in prokaryotic cells: Provided herein are prokaryotic cells capable of producing bioconjugates comprising glycosylated proteins. Also provided herein are compositions comprising such bioconjugates and/or comprising the saccharide moieties of such bioconjugates, as well as methods of vaccinating subjects using such compositions.... Agent: Glycovaxyn Ag
20140336367 - Recombinant nel-like (nell) protein production: The present invention provides a method and system for producing a NELL protein. The method and system comprise a CELL encoding a NELL protein or peptide and a non-insect secretory signal peptide.... Agent: The Regents Of The University Of CaliforniaPrevious industry: Synthetic resins or natural rubbers -- part of the class 520 series
Next industry: Organic compounds -- part of the class -570 series
RSS FEED for 20141204:
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.
Thank you for viewing Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patents we recommend signing up for free keyword monitoring by email.
Results in 0.36477 seconds